A Randomized Phase 3 Trial of Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
COG-ANHL1931
NCT04759586
 Recruiting
|
CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE
|
|
|
A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] With MK-3475 [Pembrolizumab] Coformulation) in Participants With Relapsed or Refractory Hematological Malignancies
MK-7684A-004 (KEYVIBE-004)
NCT05005442
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
|
|
Charlotte Golden
514-934-1934 poste 34909
|
A Phase 2 Study of Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary Central Nervous System Lymphoma
I244
NCT05998642
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Philippe Nadeau
418-649-0252 poste 63115
|
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies
BGB-16673-101
NCT05006716
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Maryse Gingras
418-525-4444 poste 67322
|
A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
GCT3013-05
NCT04628494
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Philippe Nadeau
418-649-0252 poste 63115
|
A Randomized Phase 3 Trial of Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
COG-ANHL1931
NCT04759586
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
CHUL ET CENTRE MERE-ENFANT SOLEIL
|
|
|
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma
OLYMPIA-1
NCT06091254
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Philippe Nadeau
418-649-0252 poste 63115
|
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma
EPCORE FL-1
NCT05409066
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Philippe Nadeau
418-649-0252 poste 63115
|
A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
SYMPHONY-1 (EZH-302)
NCT04224493
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Chantal Gosselin
514-890-8000 poste 24892
|
Phase I Trial of PCLX-001 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies
PCLX-001-01
NCT04836195
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Adeline Hamon
514-890-8000 poste 30737
|
Groupe d'étude en oncologie du Québec